Guest: Leonard H. Calabrese, DO <br>

  Guest: John R. Tesser, MD <br>


  
    <p>This activity provides patient and practice-specific biosimilars content for clinicians in rheumatology practice.</p>

FDA Review: Adding LABAs to ICS Treatment Does Not Significantly Increase Serious Asthma Outcomes Risk

Experts from the U.S. Food and Drug Administration (FDA) discuss important new drug information as well as urgent insights about approved drug products.